Clinical Trial Update: Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating pemetrexed with platinum-based chemotherapy and pembrolizumab, with or without lenvatinib, as first-line therapy for metastatic nonsqua…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Lenvatinib (lenvatinib)
• Pembrolizumab (pembrolizumab)
• Pemetrexed (pemetrexed)
• Platinum-based chemotherapy (platinum-based chemotherapy)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Nonsquamous Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED | Results posted: 2025-02-21